Lexaria Bioscience Corp. (LEXX)
11.68
+0.64
(+5.80%)
USD |
NASDAQ |
Aug 27, 16:00
11.40
-0.28
(-2.40%)
After-Hours: 20:00
Lexaria Bioscience Cash from Financing (Quarterly) : 0.00 for May 31, 2026
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | 0.00 |
| February 28, 2026 | 3.044M |
| November 30, 2025 | 3.474M |
| August 31, 2025 | 0.00 |
| May 31, 2025 | 1.689M |
| February 28, 2025 | 0.0117M |
| November 30, 2024 | 4.345M |
| August 31, 2024 | 0.00 |
| May 31, 2024 | 5.043M |
| February 29, 2024 | 3.453M |
| November 30, 2023 | 1.819M |
| August 31, 2023 | |
| May 31, 2023 | 1.711M |
| February 28, 2023 | 0.00 |
| November 30, 2022 | 0.00 |
| August 31, 2022 | -0.0112M |
| May 31, 2022 | -0.0112M |
| February 28, 2022 | -0.0112M |
| November 30, 2021 | -0.011M |
| August 31, 2021 | 3.972M |
| May 31, 2021 | 0.00 |
| February 28, 2021 | 9.448M |
| November 30, 2020 | 0.00 |
| August 31, 2020 | -0.0892M |
| May 31, 2020 | 1.916M |
| Date | Value |
|---|---|
| February 29, 2020 | 0.1203M |
| November 30, 2019 | 0.7067M |
| August 31, 2019 | 0.0992M |
| May 31, 2019 | 1.243M |
| February 28, 2019 | 0.3813M |
| November 30, 2018 | 1.649M |
| August 31, 2018 | 0.5264M |
| May 31, 2018 | 0.3355M |
| February 28, 2018 | 0.7058M |
| November 30, 2017 | 0.2647M |
| August 31, 2017 | -0.141M |
| May 31, 2017 | 2.869M |
| February 28, 2017 | 0.8835M |
| November 30, 2016 | 0.1455M |
| August 31, 2016 | 0.3218M |
| May 31, 2016 | 0.1055M |
| February 29, 2016 | 0.051M |
| November 30, 2015 | 0.036M |
| August 31, 2015 | 0.0049M |
| May 31, 2015 | 0.4671M |
| February 28, 2015 | 0.00 |
| November 30, 2014 | -0.0987M |
| October 31, 2014 | |
| July 31, 2014 | -0.0988M |
| April 30, 2014 | 1.051M |
Cash From Financing Definition
Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Target Group, Inc. (Canada) | 0.0309M |
| InMed Pharmaceuticals, Inc. | 0.2315M |
| NervGen Pharma Corp. | 56.43M |
| Milestone Pharmaceuticals, Inc. | 8.652M |
| Clearmind Medicine, Inc. | 4.653M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.635M |
| Cash from Investing (Quarterly) | -0.0271M |
| Free Cash Flow | -7.527M |
| Free Cash Flow Per Share (Quarterly) | -1.005 |
| Free Cash Flow to Equity (Quarterly) | -1.654M |
| Free Cash Flow to Firm (Quarterly) | -1.661M |
| Free Cash Flow Yield | -42.88% |